CLINICAL USE OF FK506 AS PRIMARY ANTI-REJECTION AGENT IN RENAL ALLOGRAFT RECIPEINTS

Zongming LIN,Yongkang ZHANG,Guomin Wang,Tongyu ZHU,Ruiming RONG,Yinzhong FANG,Jingen JIANG
DOI: https://doi.org/10.3969/j.issn.1006-298X.2000.03.011
2000-01-01
Abstract:OBJECTIVE To report our primary experience with the efficacy and safety of FK506 in the prevention of renal allograft re-jection. METHODOLOGY Between Oct 1998 and Feb 2000,22 cases of renal recipients (male/female 17/5)administeredFK506 as the primary anti-rejection agent in their anti-rejection regime(FK506, MMF, steroid). For the 18 patients who startedFK506 treatment after transplantation,the initial dosage of FK506 was 0.2 mg/(kg·d) with the trough serum concentration about6-15 μg/L, and the dosage was tailed off within the first 6 months, and trough serum level of FK506 maintained at 3-12 μg/L there-after. For the 4 patients switched from cyclosporin A treatment to FK506 treatment,FK506 was started at 0.2mg/(kg·d) and ad-justed to maintained the trough serrum level in the rang of 3-12 μg/L. RESULTS In patients started FK506 treatment after op-eration, there was no loss of graft or patients, nor rejection episodes observed. In 2 patients switched from CsA for hepatoxicity, hep-atic function recovered to normal, and in another 2 patients switched fiom CsA for chronic renal graft rejection, serum creatinine re-mained stable. Hyperglycemia was observed in 4( 18.2% ), hypertension in 5(22.7% ), respiratory infection in 2(9.1% ), urinarytract infection in 3( 13.6% ). CONCLUSION FK506 used as a primary anti-rejection agent is effective and safe in renal graftrecipients. Combination of FK506 and MMF plus steroids is the best regime for the prevention of both acute and chronic rejection.
What problem does this paper attempt to address?